破骨细胞
多发性骨髓瘤
下调和上调
成骨细胞
体内
癌症研究
细胞生长
骨病
体外
骨重建
医学
细胞
细胞培养
药理学
不利影响
骨溶解
临床试验
化学
细胞周期
信号转导
骨吸收
作用机理
治疗方法
骨肉瘤
治疗效果
疾病
骨髓
作者
Jinjun Qian,Jiale Zhang,Zhendong Deng,戈小洁,Cheng Wang,Shanliang Sun,Xichao Yu,Hongjie Wu,Xiangtu Kong,Jinrui Wei,Wenhao Yang,Xiaosu Feng,Song Ye,Chunyan Gu,Ye Yang,Haiwen Ni
出处
期刊:Phytomedicine
[Elsevier BV]
日期:2026-09-07
卷期号:162: 158783-158783
标识
DOI:10.1016/j.phymed.2026.158783
摘要
BACKGROUND: Multiple myeloma (MM)-associated bone disease (MBD) is a devastating complication characterized by osteolytic lesions and poor survival. Xuanbi Xiaoliu Formula (XBXLF), an herbal formula for MM, has demonstrated promising therapeutic effects; however, its mechanism of action remains unclear. This study aimed to elucidate the pharmacological actions of XBXLF against MM, with a specific focus on its effects on MBD. METHODS: We employed an integrated approach combining a clinical trial, in vitro and in vivo models, serum pharmacochemistry, UPLC-MS/MS-based metabolomics, single-cell RNA sequencing, and molecular docking/CETSA assays. Functional experiments were performed using KMS28PE/CAG cell lines and RAW264.7 osteoclastogenesis models treated with XBXLF-containing serum or its identified components to investigate the underlying mechanisms. RESULTS: In MM patients with MBD, XBXLF add-on therapy significantly improved survival and quality of life, while reducing adverse events and bone pain markers. In murine models, XBXLF inhibited bone loss and osteoclastogenesis and promoted osteoblast activity. Mechanistically, serum containing XBXLF metabolites dose-dependently suppressed MM cell proliferation and osteoclast formation. RNA-seq analysis identified downregulation of CREBBP as a key event. Saponarin and 3-Hydroxycinnamic acid were identified as the major circulating bioactive components following XBXLF administration. Importantly, Saponarin directly bound to CREBBP and downregulated c-Myc, thereby inhibiting both MM cell proliferation and osteoclast differentiation. CONCLUSION: This study demonstrates that XBXLF improves clinical outcomes in MBD by modulating the CREBBP/c-Myc pathway through its active component Saponarin. These findings reveal a novel therapeutic strategy for MBD and provide a scientific basis for integrating XBXLF into combined treatment regimens for MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI